The Cancer Prevention and Control Research Program is a reorganized version of a program presented in the last CCSG renewal. It is directed by Dr. Sidney Winawer, with Dr. Kenneth Offit listed as Vice Chairman. The application lists 54 members, with a total of approximately $10 million in research support. The research activity in the program is divided into seven major research """"""""projects"""""""" or focus areas, each of which has one or more senior leaders.
Three specific aims are described for this program that are diversely related to cancer prevention and control activity through studies at the genetic, environmental and behavioral levels. Scientific directions for the program are monitored by an advisory committee that interacts closely with MSKCC's Research Council. The specific research projects in this program include: colorectal cancer prevention (Winawer), epidemiology research (Begg), human genetics research (Chaganti, Luzzatto, and Offit), molecular pathology research (Cordon-Cardo), nutrition and chemoprevention (Shike), pain and palliative care (Foley and Portenoy), and psychiatry and behavioral sciences research (Holland). This organizational structure reflects a change since the last renewal by inclusion of the human genetics research group, the addition of Dr. Offit as Vice Chairman, and the inclusion of the molecular pathology and cancer genetics research activities. The application describes these multidisciplinary elements and their relationship to the specific aims of the program in detail. A common theme related to the recent investments and recruitments in human genetics is described. Cancer prevention and control research, in particular populationbased studies, are described as a high priority for the Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-37
Application #
6563641
Study Section
Project Start
2002-01-30
Project End
2002-12-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
37
Fiscal Year
2002
Total Cost
$157,506
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Moo, Tracy-Ann; Edelweiss, Marcia; Hajiyeva, Sabina et al. (2018) Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Ann Surg Oncol 25:1488-1494
Kinsley, Karen; Pritchett, Wendy (2018) Liposomal Irinotecan: Nursing Considerations in an Outpatient Cancer Center Clin J Oncol Nurs 22:221-224
Vargas, Hebert Alberto; Kramer, Gem M; Scott, Andrew M et al. (2018) Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med 59:1516-1523
Ho, A L (2018) Developing androgen receptor targeting for salivary gland cancers. Ann Oncol 29:792-794
Gupta, Piyush; Migliacci, Jocelyn C; Hay, Ashley et al. (2018) Validation and assessment of discordance of the 8th edition AJCC (American Joint Committee on Cancer) clinical and pathologic staging systems in patients with p16+ oropharyngeal cancer treated with surgery and adjuvant radiation at a single institution. Oral Oncol 83:140-146
Aras, Omer; Pearce, Gillian; Watkins, Adam J et al. (2018) An in-vivo pilot study into the effects of FDG-mNP in cancer in mice. PLoS One 13:e0202482
Chou, Chun; Li, Ming O (2018) Tissue-Resident Lymphocytes Across Innate and Adaptive Lineages. Front Immunol 9:2104
Quezada-Diaz, Felipe; Jimenez-Rodriguez, Rosa M; Pappou, Emmanouil P et al. (2018) Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. J Gastrointest Surg :
Schleicher, Stephen M; Bach, Peter B; Matsoukas, Konstantina et al. (2018) Medication overuse in oncology: current trends and future implications for patients and society. Lancet Oncol 19:e200-e208
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468

Showing the most recent 10 out of 8799 publications